Collaboration Agreement - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions			1 Months Ended		12 Months Ended
	Dec. 28, 2023	Jan. 31, 2023	Dec. 31, 2023	Jan. 31, 2023	Dec. 31, 2023	Jan. 26, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Development milestone payment included in transaction price			$ 68.3		$ 68.3
Kite Collaboration Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Non-refundable upfront payment received	$ 85.0			$ 225.0	225.0
Transaction price			310.5		310.5
Reduction of deemed discount on shares sold			15.3		15.3	$ 15.3
Increase in pre-effective date costs			11.2		11.2
Increase in deemed premium on shares sold	$ 15.6
Net payment to kite included in transaction price			79.3		$ 79.3
Kite Collaboration Agreement | Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of Reimbursement costs					50.00%
Kite Collaboration Agreement | Minimum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of Reimbursement costs					40.00%
Kite Collaboration Agreement and Amendment | United States
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of out-of-pocket development costs for co-promote products					40.00%
Kite Collaboration Agreement and Amendment | Kite Pharma, Inc. | Outside United States
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of out-of-pocket development costs for co-promote products					60.00%
Kite Collaboration Agreement and Amendment | Anito-cel | Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential payments of clinical, regulatory and commercial milestones					$ 598.3
Kite Collaboration Agreement and Amendment | Next Generation Autologous CAR-T Cell Therapy Product | Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential payments of clinical, regulatory and commercial milestones					935.0
Kite Collaboration Agreement and Amendment | Non-autologous CAR-T Cell Therapy Product | Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential payments of clinical, regulatory and commercial milestones					507.5
Amended Kite Collaboration Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Non-refundable upfront payment received			85.0		85.0
Increase in deemed premium on shares sold			$ 15.6		$ 15.6
Gilead Common Stock Purchase Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Issuance of common stock, net of transaction costs, shares		3,478,261
Shares issued, price per share		$ 28.75	$ 28.75	$ 28.75	$ 28.75
Reduction of deemed discount on shares sold		$ 15.3		$ 15.3
Gilead Common Stock Purchase Agreement | Gilead
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Issuance of common stock, net of transaction costs, value					$ 100.0
Second Gilead Common Stock Purchase Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Issuance of common stock, net of transaction costs, shares					3,242,542
Shares issued, price per share			$ 61.68		$ 61.68
Increase in deemed premium on shares sold			$ 15.6		$ 15.6
Second Gilead Common Stock Purchase Agreement | Gilead
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Issuance of common stock, net of transaction costs, value					$ 200.0